A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma

P. H M De Mulder, P. Cappelaere, F. Cognetti, J. Verweij, J. H. Schornagel, J. B. Vermorken, A. Kirkpatrick, J. L. Lefebvre

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Head and neck squamous carcinoma (HNSCC) is a chemotherapy-sensitive tumour, but this sensitivity is not reflected in an impact on survival. The study of new drugs is therefore indicated. Pirarubicin (4′-O-tetrahydropyranyl-doxorubicin) has a higher preclinical index than doxorubicin, with low cardiotoxicity in animal models. Patients and methods: Twenty-six patients with squamous cell carcinoma of the head and neck and documented progression after or during previous chemotherapy were entered into the study. Two patients were ineligible for evaluation. Pirarubicin was given at a dose of 70 mg/m2 every 3 weeks. Results: Partial remission was seen in 1 of the 24 evaluable patients. The predominant toxicity was bone marrow depression, with leucopenia in 62% of the patients. One patient died due to a gastrointestinal haemorrhage during a period with WHO grade IV thrombocytopenia. Conclusion: On the basis of these results, pirarubicin cannot be recommended as second-line treatment in patients with recurrent and metastatic HNSCC. Its possible relevance for first-line treatment cannot be judged from these data.

Original languageEnglish
Pages (from-to)438-440
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume33
Issue number5
DOIs
Publication statusPublished - Sep 1994

Fingerprint

Chemotherapy
Doxorubicin
Toxicity
Tumors
Bone
Animals
Squamous Cell Carcinoma
Neck
Head
Drug Therapy
Gastrointestinal Hemorrhage
Pharmaceutical Preparations
Leukopenia
Epithelial Cells
pirarubicin
Carcinoma, squamous cell of head and neck
Thrombocytopenia
Animal Models
Bone Marrow
Survival

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

De Mulder, P. H. M., Cappelaere, P., Cognetti, F., Verweij, J., Schornagel, J. H., Vermorken, J. B., ... Lefebvre, J. L. (1994). A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma. Cancer Chemotherapy and Pharmacology, 33(5), 438-440. https://doi.org/10.1007/BF00686275

A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma. / De Mulder, P. H M; Cappelaere, P.; Cognetti, F.; Verweij, J.; Schornagel, J. H.; Vermorken, J. B.; Kirkpatrick, A.; Lefebvre, J. L.

In: Cancer Chemotherapy and Pharmacology, Vol. 33, No. 5, 09.1994, p. 438-440.

Research output: Contribution to journalArticle

De Mulder, PHM, Cappelaere, P, Cognetti, F, Verweij, J, Schornagel, JH, Vermorken, JB, Kirkpatrick, A & Lefebvre, JL 1994, 'A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma', Cancer Chemotherapy and Pharmacology, vol. 33, no. 5, pp. 438-440. https://doi.org/10.1007/BF00686275
De Mulder, P. H M ; Cappelaere, P. ; Cognetti, F. ; Verweij, J. ; Schornagel, J. H. ; Vermorken, J. B. ; Kirkpatrick, A. ; Lefebvre, J. L. / A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma. In: Cancer Chemotherapy and Pharmacology. 1994 ; Vol. 33, No. 5. pp. 438-440.
@article{ec7d1b6582ba44f1ad497aa1c430a408,
title = "A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma",
abstract = "Background: Head and neck squamous carcinoma (HNSCC) is a chemotherapy-sensitive tumour, but this sensitivity is not reflected in an impact on survival. The study of new drugs is therefore indicated. Pirarubicin (4′-O-tetrahydropyranyl-doxorubicin) has a higher preclinical index than doxorubicin, with low cardiotoxicity in animal models. Patients and methods: Twenty-six patients with squamous cell carcinoma of the head and neck and documented progression after or during previous chemotherapy were entered into the study. Two patients were ineligible for evaluation. Pirarubicin was given at a dose of 70 mg/m2 every 3 weeks. Results: Partial remission was seen in 1 of the 24 evaluable patients. The predominant toxicity was bone marrow depression, with leucopenia in 62{\%} of the patients. One patient died due to a gastrointestinal haemorrhage during a period with WHO grade IV thrombocytopenia. Conclusion: On the basis of these results, pirarubicin cannot be recommended as second-line treatment in patients with recurrent and metastatic HNSCC. Its possible relevance for first-line treatment cannot be judged from these data.",
author = "{De Mulder}, {P. H M} and P. Cappelaere and F. Cognetti and J. Verweij and Schornagel, {J. H.} and Vermorken, {J. B.} and A. Kirkpatrick and Lefebvre, {J. L.}",
year = "1994",
month = "9",
doi = "10.1007/BF00686275",
language = "English",
volume = "33",
pages = "438--440",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma

AU - De Mulder, P. H M

AU - Cappelaere, P.

AU - Cognetti, F.

AU - Verweij, J.

AU - Schornagel, J. H.

AU - Vermorken, J. B.

AU - Kirkpatrick, A.

AU - Lefebvre, J. L.

PY - 1994/9

Y1 - 1994/9

N2 - Background: Head and neck squamous carcinoma (HNSCC) is a chemotherapy-sensitive tumour, but this sensitivity is not reflected in an impact on survival. The study of new drugs is therefore indicated. Pirarubicin (4′-O-tetrahydropyranyl-doxorubicin) has a higher preclinical index than doxorubicin, with low cardiotoxicity in animal models. Patients and methods: Twenty-six patients with squamous cell carcinoma of the head and neck and documented progression after or during previous chemotherapy were entered into the study. Two patients were ineligible for evaluation. Pirarubicin was given at a dose of 70 mg/m2 every 3 weeks. Results: Partial remission was seen in 1 of the 24 evaluable patients. The predominant toxicity was bone marrow depression, with leucopenia in 62% of the patients. One patient died due to a gastrointestinal haemorrhage during a period with WHO grade IV thrombocytopenia. Conclusion: On the basis of these results, pirarubicin cannot be recommended as second-line treatment in patients with recurrent and metastatic HNSCC. Its possible relevance for first-line treatment cannot be judged from these data.

AB - Background: Head and neck squamous carcinoma (HNSCC) is a chemotherapy-sensitive tumour, but this sensitivity is not reflected in an impact on survival. The study of new drugs is therefore indicated. Pirarubicin (4′-O-tetrahydropyranyl-doxorubicin) has a higher preclinical index than doxorubicin, with low cardiotoxicity in animal models. Patients and methods: Twenty-six patients with squamous cell carcinoma of the head and neck and documented progression after or during previous chemotherapy were entered into the study. Two patients were ineligible for evaluation. Pirarubicin was given at a dose of 70 mg/m2 every 3 weeks. Results: Partial remission was seen in 1 of the 24 evaluable patients. The predominant toxicity was bone marrow depression, with leucopenia in 62% of the patients. One patient died due to a gastrointestinal haemorrhage during a period with WHO grade IV thrombocytopenia. Conclusion: On the basis of these results, pirarubicin cannot be recommended as second-line treatment in patients with recurrent and metastatic HNSCC. Its possible relevance for first-line treatment cannot be judged from these data.

UR - http://www.scopus.com/inward/record.url?scp=0028078647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028078647&partnerID=8YFLogxK

U2 - 10.1007/BF00686275

DO - 10.1007/BF00686275

M3 - Article

C2 - 8306420

AN - SCOPUS:0028078647

VL - 33

SP - 438

EP - 440

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -